Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 4/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 5/20 | 0.34 |
| ▸ | CA2 | P00918 | 4/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | MMP9 | P14780 | 2/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL17508566 | 1.00 | THRB (0.59) | THRBMEN1KMT2ACA12CA9 | |
| Sulfuric Acid SCHEMBL7095704 | 0.97 | THRB (0.56) | THRBMEN1KMT2ACA12CA9 | |
| Sulfuric Acid SCHEMBL28630346 | 0.97 | THRB (0.56) | THRBMEN1KMT2ACA12CA9 | |
| Sulfuric Acid SCHEMBL9518722 | 0.97 | THRB (0.56) | THRBMEN1KMT2ACA12CA9 | |
| Sulfuric Acid SCHEMBL7095701 | 0.92 | THRB (0.56) | THRBMEN1KMT2ACA12CA9 | |
| Sulfuric Acid SCHEMBL15711221 | 0.92 | THRB (0.47) | THRBMEN1KMT2ACA12CA9 | |
| Sulfuric Acid SCHEMBL7095702 | 0.92 | THRB (0.56) | THRBMEN1KMT2ACA12CA9 | |
| SCHEMBL30432108 | 0.89 | THRB (0.53) | THRBMEN1KMT2ACA12CA9 | |
| Sulfuric Acid SCHEMBL15899380 | 0.85 | THRB (0.37) | THRBMEN1KMT2A | |
| Methane SCHEMBL4419726 | 0.83 | THRB (0.53) | THRBMEN1KMT2ACA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10434174-B2 | Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-10-08 | — | — | US | claimed |
| US-20170119883-A1 | COMBINATION THERAPIES USING PLATINUM AGENTS AND AGENTS THAT TARGET TUMOR-ASSOCIATED STROMA OR TUMOR CELLS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2017-05-04 | — | — | US | claimed |
| EP-4108248-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | Biomed Valley Discoveries, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20220378852-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | THE JOHNS HOPKINS UNIVERSITY | 2022-12-01 | — | — | US | disclosed |
| EP-3730146-B1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3730146-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | Biomed Valley Discoveries, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200330525-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | THE JOHNS HOPKINS UNIVERSITY | 2020-10-22 | — | — | US | disclosed |
| EP-3250291-B1 | CRYSTALLINE C21H22C12N4O2 MALONATE | BIOMED VALLEY DISCOVERIES INC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10738027-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| EP-2988760-B1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | BIOMED VALLEY DISCOVERIES INC (US) | 2020-06-17 | — | — | EP | disclosed |
| US-10617723-B2 | C. novyi for the treatment of solid tumors in humans | BIOMED VALLEY DISCOVERIES, INC. (US) | 2020-04-14 | — | — | US | disclosed |
| US-20160221988-A1 | CRYSTALLINE C21H22Cl2N4O2 MALONATE | BIOMED VALLEY DISCOVERIES, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160221987-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160051597-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-02-25 | — | — | US | disclosed |
| US-20160045556-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| EP-1618117-B1 | TUMOR SELECTIVE AND BIODEGRADABLE POLYPHOSPHAZENE-PLATINUM(II) CONJUGATE ANTITUMOR AGENT, AND PREPARATION METHOD THEREOF | TRUSTEES EWHA WOMANS UNIVERSIT (KR) | 2008-04-23 | — | — | EP | disclosed |
| US-6951953-B2 | Tumor selective and biodegradable polyphosphazene-platinum(II) conjugate antitumor agent, and preparation method thereof | EWHA WOMANS UNIVERSITY (KR) | 2005-10-04 | — | — | US | disclosed |
| US-20040219127-A1 | Tumor selective and biodegradable polyphosphazene-platinum(II) conjugate antitumor agent, and preparation method thereof | EWHA WOMANS UNIVERSITY (KR) | 2004-11-04 | — | — | US | disclosed |
| EP-0341409-B1 | Platinum (II) complexes, their preparation and use as antitumour agents | BOEHRINGER MANNHEIM ITALIA (IT) | 1993-12-29 | — | — | EP | disclosed |
| EP-0341409-A1 | Platinum (II) complexes, their preparation and use as antitumour agents | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1989-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10617723-B2 | C. novyi for the treatment of solid tumors in humans | HCCS, MKI67, PBK | THRB 3868/4885MEN1 3094/4885KMT2A 3743/4885 |
| US-20160045556-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | MKI67, HCCS, NCF1 | THRB 4111/4885MEN1 3729/4885KMT2A 3807/4885 |
| US-20160051597-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | HCCS, MKI67, PBK | THRB 3868/4885MEN1 3094/4885KMT2A 3743/4885 |
| US-20160221988-A1 | CRYSTALLINE C21H22Cl2N4O2 MALONATE | MAL2, ME1, SLC22A11 | THRB 4588/4885MEN1 37/4885KMT2A 3342/4885 |
| US-20220378852-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | HCCS, MKI67, PBK | THRB 3868/4885MEN1 3094/4885KMT2A 3743/4885 |
| US-20170119883-A1 | COMBINATION THERAPIES USING PLATINUM AGENTS AND AGENTS THAT TARGET TUMOR-ASSOCIATED STROMA OR TUMOR CELLS | CXCL12, CD47, TP53 | THRB 2992/4885MEN1 2017/4885KMT2A 3269/4885 |
| US-10738027-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | THRB 3667/4885MEN1 63/4885KMT2A 2938/4885 |
| US-20160221987-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | THRB 3667/4885MEN1 63/4885KMT2A 2938/4885 |
| US-20200330525-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | HCCS, MKI67, PBK | THRB 3868/4885MEN1 3094/4885KMT2A 3743/4885 |
| US-20040219127-A1 | Tumor selective and biodegradable polyphosphazene-platinum(II) conjugate antitumor agent, and preparation method thereof | PHOSPHO1, FOLR1, PCNA | THRB 3696/4885MEN1 386/4885KMT2A 1444/4885 |
| US-10434174-B2 | Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells | CXCL12, CD47, TP53 | THRB 2992/4885MEN1 2017/4885KMT2A 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.